Despite their potential, there are several challenges in biomarker research. One significant challenge is the heterogeneity of cancer, meaning that different patients with the same type of cancer can have different biomarkers. Another challenge is the need for high sensitivity and specificity in detecting biomarkers to avoid false positives and negatives. Additionally, the development of biomarkers into clinically useful tests involves rigorous validation and regulatory approval processes.
